OnKure Therapeutics, Inc. (OKUR)
NASDAQ: OKUR · Real-Time Price · USD
2.530
-0.010 (-0.39%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Company Description
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.
Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
The company is headquartered in Boulder, Colorado.
OnKure Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Nicholas Saccomano |
Contact Details
Address: 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 United States | |
| Phone | 720 307 2892 |
| Website | onkuretherapeutics.com |
Stock Details
| Ticker Symbol | OKUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001637715 |
| ISIN Number | US68277Q1058 |
| Employer ID | 47-2309515 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, Chief Executive Officer and Director |
| Jason A. Leverone CPA | Chief Financial Officer |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Rogan P. Nunn J.D. | General Counsel and Secretary |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Duncan Walker Ph.D. | Chief Development Officer |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK and Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Roberta Alton | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | ARS | Filing |
| Mar 24, 2025 | 424B3 | Prospectus |
| Mar 21, 2025 | EFFECT | Notice of Effectiveness |
| Mar 20, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2025 | 424B3 | Prospectus |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 10-K | Annual Report |